The latest update is out from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ).
Shanghai Junshi Biosciences Co., Ltd. announced updates regarding the shareholding of its largest shareholder, Mr. Xiong Jun, who is also the chairman and an executive director of the company. Mr. Xiong has entered into new concert party agreements, which have adjusted the composition of the shareholder group, resulting in a 18.67% interest in the company’s total issued share capital. Additionally, Mr. Xiong plans to increase his shareholding by at least RMB100 million over the next 12 months, reflecting his confidence in the company’s future development and long-term investment value. This move may strengthen his influence within the company and potentially impact the company’s market positioning.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biotechnology company based in China, primarily focused on the development and commercialization of innovative therapies. The company operates within the pharmaceutical industry, with a market focus on biologics and immunotherapy treatments.
YTD Price Performance: 17.62%
Average Trading Volume: 2,009,983
Technical Sentiment Signal: Buy
Current Market Cap: HK$25.46B
See more insights into 1877 stock on TipRanks’ Stock Analysis page.